Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

BACKGROUND: The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards. However, the growth in the number of licensed orphan medicinal products (OMPs) has led to concerns...

Descripción completa

Detalles Bibliográficos
Autores principales: Pijeira Perez, Yankier, Wood, Eifiona, Hughes, Dyfrig A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621215/
https://www.ncbi.nlm.nih.gov/pubmed/37915031
http://dx.doi.org/10.1186/s13023-023-02956-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621215/
https://www.ncbi.nlm.nih.gov/pubmed/37915031
http://dx.doi.org/10.1186/s13023-023-02956-3

Ejemplares similares